The Neurotechnology Industy Investing and Business Conference (The Neurotech Indust)
Venue: Westin San Francisco Airport
|Event Date/Time: May 18, 2006||End Date/Time: May 18, 2006|
|Registration Date: May 17, 2006|
|Early Registration Date: Mar 01, 2006|
This market defining conference features keynotes presentations on state of the neurotech industry, cutting edge company presentations, and panel discussions on a comprehensive selection of neurotech topics.
Hear about next generation treatments for Alzheimer's, addiciton, anxiety, depression, pain, sensory disorders, obesity, stroke, schizophrenia, sleep disorders, epilepsy, Parkinson's and more.
Thursday May 18, 2006
7:30 - 8:00 Continental Breakfast & Registration
8:00 - 8:30 Welcome: The Global Neurotech Industry 2006
NeuroInsights reveals updated proprietary market data, revenue projections, and industry trends.
8:30 - 9:15 Investing in Neurotech
A diverse panel of neurotech venture capitalists and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are alternative fund raising strategies? What are the benefits and risks of business models in devices, pharmaceuticals, and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
9:15-10:15 Strategies in Memory, Cognitive Impairment & Alzheimer's
As the population ages, the market for memory, cognitive impairment, and Alzheimer’s treatments is exploding. What are the latest strategies for treating memory decline? While the FDA has approved the category mild cognitive impairment (MCI), is there a clear path to patient identification and drug approval? Are we closer to curing Alzheimer’s disease? What are the technical, preclinical and clinical challenges? How are companies leveraging expertise and leads into other indications?
10:15 - 10:30 Networking and Refreshment Break
10:30 -11:30 Corporate Partnering and Licensing in Neurotech
Big pharma, biotech and medtech increasingly are looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and partnering? Is there a new model for partnerships emerging? Is Big pharma still a good partner for neurotech? Can small neurotech companies team up to commercialize products?
11:15 -12:00 Advances in Brain Imaging and NeuroInformatics
The quest to develop increasingly more effective neurotherapeutics and diagnostics depends upon continuously higher quality molecular, cellular and systems level information about the brain. The goal of neuroinformatics is to provide standardized, quantitative datasets that allow the rapid comparison of patient profiles against normative data, including genetic, brain imaging, lifestyle and symptom information. How are neuroinformatics databases currently being used to improve drug development? What are the current capabilities and limitations of neuroimaging technologies (MRI, fMRI, CT, & PET)? Are there advances in imaging and informatics on the horizon that could dramatically impact therapeutic development or diagnostics?
12:00 -1:30 Luncheon Keynote
1:30 - 2:30 The Future of Neuropsychiatry and Specialty Pharmaceuticals
Revenues from anxiety, depression, schizophrenia and other neuropsychiatric illnesses continue to rise. How is polypharmacy, the use of multiple drugs to treat an illness, playing a role in drug development strategies? How and why are companies creating new market categories for their compounds? Are there advantages in neuropsychiatry for “multiple shots on goal?” How are companies using in-licensing and out-licensing to compete in these markets? What are the unique investment risks and payoffs?
2:30 - 3:15 Spinning Neurotech out of the Lab
Industry relies on institutes and universities for basic research which will eventually lead to breakthrough treatments. Learn new models and effective strategies for technology transfer and industry collaboration from leading edge organizations in neurotech. How do serial entrepreneurs bridge the divide between basic research and commercial solutions? What is the cutting edge science that will influence the next generation of products?
3:15 - 3:30 Networking and Refreshment Break
3:30 - 4:30 Neurodevices: Is Neuro the next Cardio?
Neurostimulation devices are gaining ground in markets like pain and Parkinson's disease, while new approvals and innovative startups are showing that neurostimulation can be applied to markets like depression, epilepsy, obesity, stroke, spinal cord injury, urinary incontinence, and others. Where are the best opportunities for devices to compete with or displace drugs? While medical devices have traditionally had a faster path to market, does this apply for neurodevices too? Can neurodevices compete in cost and efficiency? What are the current reimbursement issues for neurodevices?
4:30 - 5:30 Neuroregeneration: Stem Cells and Other Strategies
The regeneration or replacement of nerve cells is the holy grail of neurological disease therapy. What is the state of innovative therapies to promote neuronal regeneration? What is a realistic time frame for product candidates to begin reaching the clinic? What are the unique technical and regulatory hurdles that must be overcome for the safe and effective development of stem cell products in treating neurological disease?
5:30 - 7:00 Cocktail Reception